Partnering is at the core of our business: we collaborate to unlock the potential of cutting-edge science and advance patient care. From our focused R&D engine to high-quality manufacturing and novel access approaches, we have the expertise and capabilities to bring high-value treatments to millions of people around the globe.
Susanne Kreutz, Global Head Corporate & Business Development
Our goal is to create long-lasting partnerships that generate joint value and advance patient care. Regardless of your development stage or partnering needs, reach out and we will work together to define our collaboration.
We look for areas of interest and mutual goals
We conduct diligences with flexibility and efficiency
We shape a deal that creates mutual value
We build long-term, sustainable partnerships
“Our Search & Evaluation team looks for partnering opportunities that bring cutting edge science and transformative medicines to patients. From our very first conversation we begin as we mean to continue: with transparency, fairness, and a clear focus on our mutual goals.”
Adam Feire, Global Head Search & Evaluation
“Diligences at Novartis are performed with dedicated teams, established processes, and senior experts at the table. We acknowledge every opportunity is different and strive for the highest levels of flexibility, transparency and efficiency to exceed the expectations of our partners.”
Michaela Dehio, Global Head Due Diligence and Operations
“Recognizing the importance of collaboration to bring transformative medicines to patients, we craft tailored deals which leverage the capabilities and expertise of our partners. Throughout, we act with a sense of urgency - driving engagement, alignment and connectivity to ensure an efficient partnering process.”
Guillaume Vignon, Global Head BD&L Transactions
“Our dedicated team of alliance managers is involved as a strategic partner throughout the full life cycle of collaborations. We build trust with our partners, create sustainable value, and minimize risks in our collaborations. Our ultimate aim is to establish Novartis as the preferred company for partnering.”
Arne Wörn, Global Head Alliance Management
Novartis acquires Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases.
Novartis acquires DTx Pharma, a San-Diego based, preclinical stage biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications.
